SPOTLIGHT -
KalVista Pharmaceuticals has received a £2.4 million grant to accelerate development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema.
Sean Donahue, MD, PhD, to become president of the American Association for Pediatric Ophthalmology and Strabismus
(EyePod) From idea to impact: Navigating ophthalmic innovation
Multiple companies announce data presentations at ARVO 2024
EyePod: Modifier Gene Therapy: What is it?
Eyenovia provides clinical, scientific update on FDA-approved products Mydcombi and clobetasol propionate ophthalmic suspension
Verana Health launches its Qdata Thyroid Eye Disease module